Senate Finance Committee Members Increasingly Showing Support for China 301 Tariffs
In six short years, there is now a strong, bipartisan consensus that trade with China is a serious issue that is harming our nation, workers, and producers.
In six short years, there is now a strong, bipartisan consensus that trade with China is a serious issue that is harming our nation, workers, and producers.
For too long, federal tax and trade policy incentivized the offshoring of production and good-paying manufacturing jobs to countries like China.
Owl Labs of Massachusetts may look like an American company, but other than the U.S.-based venture capital that funds it, and the intellectual property behind it, their 360-degree video cameras are made in China.
Go to U.S. Steel’s website and it looks like a done deal: Nippon Steel, the fourth largest steel producer in the world, is already the assumed new owner of America’s oldest, most storied steel company, formed in 1901 when J.P. Morgan financed the merger of three steel companies.
The 118th Congress (2023-2024) is easily the best Congress we’ve had in the 21st century when it comes to tariff policy. U.S. Senators in particular are introducing new tariff bills for different products and industries.
The proposed acquisition of U.S. Steel by Japan’s Nippon Steel has understandably generated controversy and concern. At a gut-level, it feels wrong to many Americans.
China’s predatory auto industry is a direct threat to American auto manufacturers and the hundreds of thousands of hard-working men and women that rely on this critical industry.
An alarming new report from Horizon Advisory details China’s distortion of the global solar industry and how that threatens the national and economic security of the United States as it “risks making the United States dependent, and dependent on an adversary, for a strategic, future energy source.”
As imports from China rise, the native auto industry will whither at a time when a new auto industry is being born. Call it an opportunity lost.
The expert witness testimony made it clear that U.S. labs were treated differently than foreign ones, and despite increases in hiring at the FDA over the years, lawmakers have a lot to be concerned about when it comes to the FDA conducting proper oversight of foreign manufacturing facilities.